LIXTE BIOTECHNOLOGY HOLDINGS INC (LIXT)
NASDAQHealth CareBiotechnologySnapshot 2026-10-29
$4.43-0.45%
Close 2026-07-28 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-10-29
Research Workspace
Put LIXT beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Primary pillar under pressure — Manage capital raise impact and dilution: Dilution trip triggered.
View ThesisThis stock is volatile — it swings about 4% on a typical day and fell roughly 55% in its worst 12-month stretch.
View RiskLIXT’s case rests on a business recovery, but the desk has no earnings history to confirm growth. The latest release is also absent, so no result supports that recovery claim. The company was unprofitable over the past year, leaving earnings quality unassessable. No valuation multiple or priced-in expectations are available to define what the market reflects. The concrete risk is dilution, which the desk says has triggered pressure on a primary thesis pillar. Our read is provisional; the thesis is on watch.
Trailing returns as of 2026-07-28. LIXT is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Continue this research
Compare LIXT with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| LIXT Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 0 valuation methods, at three horizons. As of 2026-10-29. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Biotechnology — fair value, gap to price, and forward P/E.
Compare the value case
Put LIXT next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Threatens: Issue new shares for capital
Capital raise may dilute existing shares and affect valuation.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-07-28. EPS is implied from price ÷ P/E. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.